Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528447 | 1.00 | MAP4K4 (0.50) | MAP4K4CHRM4MCHR1BTKAAK1 | |
| SCHEMBL529250 | 0.93 | BTK (0.48) | MAP4K4CHRM4MCHR1BTKKDM4E | |
| SCHEMBL595852 | 0.90 | MAP4K4 (0.61) | MAP4K4CHRM4MCHR1KDM4EABL1 | |
| SCHEMBL2789586 | 0.90 | MAP4K4 (0.61) | MAP4K4CHRM4MCHR1KDM4EABL1 | |
| SCHEMBL3665883 | 0.87 | AAK1 (0.53) | MAP4K4CHRM4MCHR1AAK1 | |
| SCHEMBL4886210 | 0.85 | MAP4K4 (0.45) | MAP4K4CHRM4MCHR1AAK1 | |
| SCHEMBL1750039 | 0.84 | MAP4K4 (0.56) | MAP4K4MCHR1 | |
| SCHEMBL22165062 | 0.84 | MAP4K4 (0.56) | MAP4K4MCHR1 | |
| SCHEMBL529447 | 0.84 | MAP4K4 (0.56) | MAP4K4MCHR1 | |
| SCHEMBL2236554 | 0.84 | AAK1 (0.54) | MAP4K4CHRM4AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | MAP4K4 1267/4885CHRM4 2150/4885MCHR1 1838/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | MAP4K4 1224/4885CHRM4 2265/4885MCHR1 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.